These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36312051)

  • 21. The Threshold Effect of Leveraged Trading on the Stock Price Crash Risk: Evidence from China.
    Peng Z; Hu C
    Entropy (Basel); 2020 Feb; 22(3):. PubMed ID: 33286042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can the Market Recognize the Value of the Corporate Governance Mechanism of Chinese Listed Companies?-Empirical Evidence From COVID-19.
    Li J; Ma Y; Shi B; Yang Y
    Front Public Health; 2021; 9():812253. PubMed ID: 35155358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Firms' exposures on COVID-19 and stock price crash risk: Evidence from China.
    Kong X; Jin Y; Liu L; Xu J
    Financ Res Lett; 2023 Mar; 52():103562. PubMed ID: 36471778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The COVID-19 shock and the ownership of store Chain：Evidence from China's express delivery industry.
    Shang L; Liu Y; Xu P
    Heliyon; 2023 Oct; 9(10):e20799. PubMed ID: 37860577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the financial flexibility prevent stock price crash risk during COVID-19 crisis? Evidence from the Vietnamese stock market.
    Nguyen QK; Dang VC
    Heliyon; 2023 Nov; 9(11):e22287. PubMed ID: 38045113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlling shareholders' share pledge and share repurchase notices of listed companies.
    Cao L; Zhu X; Xie J
    PLoS One; 2024; 19(9):e0308614. PubMed ID: 39331582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research on the Effect of Executive Incentive Institutional Innovation on the Cost of Equity-Evidence From Chinese Listed Companies.
    Wang J; Deng J
    Front Psychol; 2021; 12():686955. PubMed ID: 34168600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Varying ethics rules in clinical research and routine patient care--research ethics committee chairpersons' views in Finland.
    Hemminki E; Virtanen JI; Veerus P
    Health Res Policy Syst; 2014 Mar; 12():15. PubMed ID: 24666735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent director compensation and stock price collapse: Inhibition or promotion-based on a financial background perspective.
    Dong G; Ma G; Liu S
    PLoS One; 2023; 18(8):e0289986. PubMed ID: 37561795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dataset for the analysis of stock price responses to African Swine Fever Outbreaks in China.
    Xiong T; Zhang W; Chen CT
    Data Brief; 2022 Dec; 45():108574. PubMed ID: 36131954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How does ESG performance affect stock returns? Empirical evidence from listed companies in China.
    Yin XN; Li JP; Su CW
    Heliyon; 2023 May; 9(5):e16320. PubMed ID: 37305472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can core competence help reduce stock price synchronicity? - Empirical evidence based on text analysis.
    Sun C; Sun H; Li N; Khan MA; Zhang Z
    PLoS One; 2021; 16(11):e0259409. PubMed ID: 34752465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Stock Performance of American Companies Investing in a Culture of Health.
    Goetzel RZ; Fabius R; Roemer EC; Kent KB; Berko J; Head MA; Henke RM
    Am J Health Promot; 2019 Mar; 33(3):439-447. PubMed ID: 30700099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of environmental information disclosure on stock price synchronicity in China.
    Yang Y; Zhang J; Li Y
    Heliyon; 2023 May; 9(5):e16271. PubMed ID: 37251833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can green credit increase firm value? Evidence from Chinese listed new energy companies.
    Lai X; Yue S; Chen H
    Environ Sci Pollut Res Int; 2022 Mar; 29(13):18702-18720. PubMed ID: 34697707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of China's Vaccine Incidents on the Operational Efficiency of Biopharmaceutical Companies.
    Chai KC; Tao R; Chang KC; Yang Y
    Front Public Health; 2020; 8():93. PubMed ID: 32322567
    [No Abstract]   [Full Text] [Related]  

  • 38. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.
    Gu Y; Zhuang Q
    Front Pharmacol; 2023; 14():1192423. PubMed ID: 37324496
    [No Abstract]   [Full Text] [Related]  

  • 39. Does venture capital Quan Zi affect stock mispricing: Evidence from Chinese listed companies.
    Chen P; Deng L
    PLoS One; 2023; 18(4):e0281255. PubMed ID: 37053247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of controlling person's illegalities on stock price returns: Evidence from Elman neural network model.
    Xiao M; Guo Y; Yang X; Li G; Kholaif MMNHK
    PLoS One; 2022; 17(4):e0266741. PubMed ID: 35443002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.